Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$11.79 USD
-0.20 (-1.67%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $11.82 +0.03 (0.25%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NMRA 11.79 -0.20(-1.67%)
Will NMRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRA
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
Other News for NMRA
Neumora Therapeutics’ Advancing Drug Pipeline Supports Buy Rating
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics expects cash to fund operations into 2026
Neumora Therapeutics reports Q2 EPS (37c), consensus (37c)